Topics
News
CME/CE
Editorial Advisory Board
Partnerships
Enbrel (etanercept) approved for the treatment of adult patients with chronic moderate to severe plaque psoriasis
THOUSAND OAKS, Calif. & COLLEGEVILLE, Pa.--(BUSINESS WIRE)--April 30 ? Amgen Inc. and Wyeth Pharmaceuticals, a division of Wyeth, announced Friday that Enbrel (etanercept) has been approved by the U.S. Food and Drug Administration for the treatment of adult patients with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Related Videos
Related Content
